Alosetron
- Atc Codes:A03AE01
- CAS Codes:122852-69-1#122852-42-0
- PHARMGKB ID:122852-69-1#122852-42-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Lotronex.
Drug combinations
Chemistry
Alosetron Hydrochloride: C~17~H~18~N~4~O.HCl. Mw: 330.81. (1) 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-, monohydrochloride; (2) 2,3,4,5-Tetrahydro-5-methyl-2-[(5-methylimidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one monohydrochloride. CAS-122852-69-1; CAS-122852-42-0 (alosetron)(1992).
Pharmacologic Category
Anti-Inflammatory Agents; Selective 5-HT~3~ Receptor Antagonist. (ATC-Code: A03AE01).
Mechanism of action
Potent and selective antagonist of the serotonin 5-HT~3~ receptor.
Therapeutic use
Treatment of severe diarrhea-predominant irritable bowel syndrome in women.
Pregnancy and lactiation implications
Should be used in pregnant women only if clearly needed. Caution if administered to a nursing woman.
Unlabeled use
Contraindications
Hypersensitivity to alosetron or any component of the formulation. Constipation. Ischemic colitis. Intestinal obstruction. Stricture. Toxic megacolon. Gastrointestinal perforation and/or adhesions. Diverticulitis. Crohn’s disease. Hepatic dysfunction. Ulcerative colitis. Impaired intestinal circulation, thrombophlebitis, or hypercoagulable state. Concomitant administration with fluvoxamine.
Warnings and precautions
Only indicated for women with severe diarrhea-predominant irritable bowel syndrome with inadequate response to conventional therapy. Risk of constipation. Acute ischemic colitis reported. Avoid use in severe hepatic impairment.